Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease.

Ma QL, Teng E, Zuo X, Jones M, Teter B, Zhao EY, Zhu C, Bilousova T, Gylys KH, Apostolova LG, LaDu MJ, Hossain MA, Frautschy SA, Cole GM.

Neurobiol Dis. 2018 Jun;114:120-128. doi: 10.1016/j.nbd.2018.02.014. Epub 2018 Mar 6.

PMID:
29501530
2.

Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer's Disease.

Sundaram JR, Poore CP, Sulaimee NHB, Pareek T, Cheong WF, Wenk MR, Pant HC, Frautschy SA, Low CM, Kesavapany S.

J Alzheimers Dis. 2017;60(4):1429-1442. doi: 10.3233/JAD-170093.

PMID:
29036814
3.

Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain.

Teter B, LaDu MJ, Sullivan PM, Frautschy SA, Cole GM.

Neuroreport. 2016 Aug 3;27(11):791-5. doi: 10.1097/WNR.0000000000000608.

4.

Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.

Teng E, Taylor K, Bilousova T, Weiland D, Pham T, Zuo X, Yang F, Chen PP, Glabe CG, Takacs A, Hoffman DR, Frautschy SA, Cole GM.

Neurobiol Dis. 2015 Oct;82:552-560. doi: 10.1016/j.nbd.2015.09.002. Epub 2015 Sep 12.

5.

Clinical development of curcumin in neurodegenerative disease.

Hu S, Maiti P, Ma Q, Zuo X, Jones MR, Cole GM, Frautschy SA.

Expert Rev Neurother. 2015 Jun;15(6):629-37. doi: 10.1586/14737175.2015.1044981. Review.

PMID:
26035622
6.

Neuroinflammation in Alzheimer's disease.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP.

Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. Review.

7.

Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease.

Bilousova T, Taylor K, Emirzian A, Gylys R, Frautschy SA, Cole GM, Teng E.

Neurobiol Dis. 2015 Feb;74:32-40. doi: 10.1016/j.nbd.2014.11.006. Epub 2014 Nov 13.

8.

Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging.

Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Kiosea NC, Nazari S, Chen PP, Nothias F, Chan P, Teng E, Frautschy SA, Cole GM.

J Neurosci. 2014 May 21;34(21):7124-36. doi: 10.1523/JNEUROSCI.3439-13.2014.

9.

Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.

Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA.

J Biol Chem. 2013 Feb 8;288(6):4056-65. doi: 10.1074/jbc.M112.393751. Epub 2012 Dec 21.

10.

Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers.

Attar A, Ripoli C, Riccardi E, Maiti P, Li Puma DD, Liu T, Hayes J, Jones MR, Lichti-Kaiser K, Yang F, Gale GD, Tseng CH, Tan M, Xie CW, Straudinger JL, Klärner FG, Schrader T, Frautschy SA, Grassi C, Bitan G.

Brain. 2012 Dec;135(Pt 12):3735-48. doi: 10.1093/brain/aws289. Epub 2012 Nov 26.

11.

PAK in Alzheimer disease, Huntington disease and X-linked mental retardation.

Ma QL, Yang F, Frautschy SA, Cole GM.

Cell Logist. 2012 Apr 1;2(2):117-125.

12.

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.

Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM.

Alzheimers Res Ther. 2012 Oct 29;4(5):43. doi: 10.1186/alzrt146. eCollection 2012.

13.

Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.

Hickey MA, Zhu C, Medvedeva V, Lerner RP, Patassini S, Franich NR, Maiti P, Frautschy SA, Zeitlin S, Levine MS, Chesselet MF.

Mol Neurodegener. 2012 Apr 4;7:12. doi: 10.1186/1750-1326-7-12.

14.

Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann-Pick C1.

Borbon IA, Hillman Z, Duran E Jr, Kiela PR, Frautschy SA, Erickson RP.

Pharmacol Biochem Behav. 2012 Mar;101(1):125-31. doi: 10.1016/j.pbb.2011.12.009. Epub 2011 Dec 17.

15.

[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.

Teng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, Chen PP, Cole GB, Jones MR, Huang SC, Flood DG, Trusko SP, Small GW, Cole GM, Barrio JR.

Neurobiol Dis. 2011 Sep;43(3):565-75. doi: 10.1016/j.nbd.2011.05.003. Epub 2011 May 13.

16.

What was lost in translation in the DHA trial is whom you should intend to treat.

Frautschy SA, Cole GM.

Alzheimers Res Ther. 2011 Jan 20;3(1):2. doi: 10.1186/alzrt61.

17.

Dietary fatty acids and the aging brain.

Cole GM, Ma QL, Frautschy SA.

Nutr Rev. 2010 Dec;68 Suppl 2:S102-11. doi: 10.1111/j.1753-4887.2010.00345.x. Review.

18.

Why pleiotropic interventions are needed for Alzheimer's disease.

Frautschy SA, Cole GM.

Mol Neurobiol. 2010 Jun;41(2-3):392-409. doi: 10.1007/s12035-010-8137-1. Epub 2010 May 2. Review.

19.

Thinking outside the box about COX-1 in Alzheimer's disease.

Frautschy SA.

Neurobiol Dis. 2010 Jun;38(3):492-4. doi: 10.1016/j.nbd.2010.02.009. Epub 2010 Mar 2.

20.

Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Cole GM, Frautschy SA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-8. Review.

21.

DHA may prevent age-related dementia.

Cole GM, Frautschy SA.

J Nutr. 2010 Apr;140(4):869-74. doi: 10.3945/jn.109.113910. Epub 2010 Feb 24. Review.

22.

Short-term total sleep deprivation in the rat increases antioxidant responses in multiple brain regions without impairing spontaneous alternation behavior.

Ramanathan L, Hu S, Frautschy SA, Siegel JM.

Behav Brain Res. 2010 Mar 5;207(2):305-9. doi: 10.1016/j.bbr.2009.10.014. Epub 2009 Oct 20.

23.

Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.

Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM.

J Neurosci. 2009 Jul 15;29(28):9078-89. doi: 10.1523/JNEUROSCI.1071-09.2009.

24.

Omega-3 fatty acids and dementia.

Cole GM, Ma QL, Frautschy SA.

Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):213-21. doi: 10.1016/j.plefa.2009.05.015. Epub 2009 Jun 12. Review.

25.

Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid.

Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM.

Arch Neurol. 2009 Apr;66(4):448-57. doi: 10.1001/archneurol.2009.22.

26.

Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model.

Begum AN, Yang F, Teng E, Hu S, Jones MR, Rosario ER, Beech W, Hudspeth B, Ubeda OJ, Cole GM, Frautschy SA.

J Alzheimers Dis. 2008 Dec;15(4):625-40.

27.

GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.

Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA.

Neurobiol Dis. 2009 Feb;33(2):193-206. doi: 10.1016/j.nbd.2008.10.007. Epub 2008 Nov 5.

28.

Exercise can increase small heat shock proteins (sHSP) and pre- and post-synaptic proteins in the hippocampus.

Hu S, Ying Z, Gomez-Pinilla F, Frautschy SA.

Brain Res. 2009 Jan 16;1249:191-201. doi: 10.1016/j.brainres.2008.10.054. Epub 2008 Nov 5.

29.

Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease.

Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA.

J Pharmacol Exp Ther. 2008 Jul;326(1):196-208. doi: 10.1124/jpet.108.137455. Epub 2008 Apr 16.

30.

p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis.

Ma QL, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM.

J Biol Chem. 2008 May 16;283(20):14132-43. doi: 10.1074/jbc.M708034200. Epub 2008 Mar 17.

31.

Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention.

Ma QL, Teter B, Ubeda OJ, Morihara T, Dhoot D, Nyby MD, Tuck ML, Frautschy SA, Cole GM.

J Neurosci. 2007 Dec 26;27(52):14299-307.

32.

Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models.

Ma QL, Harris-White ME, Ubeda OJ, Simmons M, Beech W, Lim GP, Teter B, Frautschy SA, Cole GM.

J Neurochem. 2007 Nov;103(4):1594-607. Epub 2007 Aug 30.

33.

Neuroprotective effects of curcumin.

Cole GM, Teter B, Frautschy SA.

Adv Exp Med Biol. 2007;595:197-212. Review.

34.
35.

The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease.

Cole GM, Frautschy SA.

Exp Gerontol. 2007 Jan-Feb;42(1-2):10-21. Epub 2006 Oct 17. Review.

PMID:
17049785
36.

Commentary on "Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery." Pleiotropic approaches to Alzheimer's and other diseases of aging.

Cole GM, Frautschy SA.

Alzheimers Dement. 2006 Oct;2(4):284-6. doi: 10.1016/j.jalz.2006.08.006. No abstract available.

PMID:
19595901
37.

Cat and mouse.

Cole GM, Frautschy SA.

Neuron. 2006 Sep 21;51(6):671-2.

38.

Alzheimer's amyloid story finds its star.

Cole GM, Frautschy SA.

Trends Mol Med. 2006 Sep;12(9):395-6. Epub 2006 Aug 1.

PMID:
16880006
39.

beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits.

Malm T, Ort M, Tähtivaara L, Jukarainen N, Goldsteins G, Puoliväli J, Nurmi A, Pussinen R, Ahtoniemi T, Miettinen TK, Kanninen K, Leskinen S, Vartiainen N, Yrjänheikki J, Laatikainen R, Harris-White ME, Koistinaho M, Frautschy SA, Bures J, Koistinaho J.

Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8852-7. Epub 2006 May 24.

40.

Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease.

Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM.

Nat Neurosci. 2006 Feb;9(2):234-42. Epub 2006 Jan 15.

PMID:
16415866
41.

Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.

Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM.

J Neurosci Res. 2006 Feb 15;83(3):374-84.

PMID:
16385556
42.

Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions.

Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautschy SA.

Neurobiol Aging. 2005 Dec;26 Suppl 1:133-6. Epub 2005 Nov 2. Review.

PMID:
16266772
43.

Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition.

Harris-White ME, Frautschy SA.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):469-80. Review.

PMID:
16266282
44.

Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease.

Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, Frautschy SA, Cole GM.

Eur J Neurosci. 2005 Aug;22(3):617-26.

PMID:
16101743
45.

Tetrahydrocurcumin in plasma and urine: quantitation by high performance liquid chromatography.

Heath DD, Pruitt MA, Brenner DE, Begum AN, Frautschy SA, Rock CL.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):206-12.

PMID:
16061427
46.

A potential role of the curry spice curcumin in Alzheimer's disease.

Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL.

Curr Alzheimer Res. 2005 Apr;2(2):131-6. Review.

47.

Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro.

Xie Z, Harris-White ME, Wals PA, Frautschy SA, Finch CE, Morgan TE.

J Neurochem. 2005 May;93(4):1038-46.

48.

A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model.

Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM.

J Neurosci. 2005 Mar 23;25(12):3032-40.

49.

Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models.

Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM.

Neuropsychopharmacology. 2005 Jun;30(6):1111-20.

50.

NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models.

Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA.

Ann N Y Acad Sci. 2004 Dec;1035:68-84. Review.

PMID:
15681801

Supplemental Content

Loading ...
Support Center